gamma-aminobutyric acid has been researched along with Premenstrual Tension in 18 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Premenstrual Tension: A term used to describe the psychological aspects of PREMENSTRUAL SYNDROME, such as the indescribable tension, depression, hostility, and increased seizure activity in women with seizure disorder.
Excerpt | Relevance | Reference |
---|---|---|
"Plasma gamma-aminobutyric acid (GABA) levels have been reported to be low in some patients with major depressive disorder." | 3.69 | Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. ( Bibi, KW; Halbreich, U; Kramer, GL; Petty, F; Rush, AJ; Yonkers, K, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (5.56) | 18.7374 |
1990's | 3 (16.67) | 18.2507 |
2000's | 5 (27.78) | 29.6817 |
2010's | 6 (33.33) | 24.3611 |
2020's | 3 (16.67) | 2.80 |
Authors | Studies |
---|---|
Gao, M | 3 |
Zhang, H | 4 |
Gao, Z | 3 |
Sun, Y | 3 |
Xu, G | 3 |
Wei, F | 3 |
Wang, J | 3 |
Gao, D | 3 |
Hantsoo, L | 2 |
Payne, JL | 1 |
Sikes-Keilp, C | 1 |
Rubinow, DR | 1 |
Gao, H | 1 |
Shang, YZ | 1 |
Xia, T | 1 |
Qiao, MQ | 1 |
Zhang, HY | 1 |
Ma, YX | 1 |
Gao, X | 1 |
Sun, P | 1 |
Qiao, M | 1 |
Wei, S | 1 |
Xue, L | 1 |
De Bondt, T | 1 |
De Belder, F | 1 |
Vanhevel, F | 1 |
Jacquemyn, Y | 1 |
Parizel, PM | 1 |
Epperson, CN | 3 |
Krüger, S | 1 |
Lindstaedt, M | 1 |
Omole, F | 1 |
Hacker, Y | 1 |
Patterson, E | 1 |
Isang, M | 1 |
Bell-Carter, D | 1 |
Sundstrom-Poromaa, I | 1 |
Smith, DH | 1 |
Gong, QH | 2 |
Sabado, TN | 1 |
Li, X | 2 |
Light, A | 1 |
Wiedmann, M | 1 |
Williams, K | 1 |
Smith, SS | 2 |
Haga, K | 1 |
Mason, GF | 2 |
Sellers, E | 1 |
Gueorguieva, R | 1 |
Zhang, W | 1 |
Weiss, E | 1 |
Rothman, DL | 2 |
Krystal, JH | 2 |
Ross, LE | 1 |
Steiner, M | 1 |
Amin, Z | 1 |
Cavus, I | 1 |
Labrum, AH | 1 |
Halbreich, U | 1 |
Petty, F | 1 |
Yonkers, K | 1 |
Kramer, GL | 1 |
Rush, AJ | 1 |
Bibi, KW | 1 |
Yonkers, KA | 1 |
Hsu, FC | 1 |
Markowitz, RS | 1 |
ffrench-Mullen, JM | 1 |
Breckwoldt, M | 1 |
Keck, Ch | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder[NCT02777372] | Phase 4 | 84 participants (Actual) | Interventional | 2016-04-01 | Completed | ||
Sex, GABA and Nicotine: A 1H-MRS Study[NCT01227343] | 54 participants (Actual) | Observational | 2010-03-31 | Completed | |||
Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen[NCT00626340] | Phase 4 | 18 participants (Actual) | Interventional | 1999-07-31 | Completed | ||
Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial[NCT02427334] | Phase 3 | 210 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | ||
The Synergistic Use of Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in the Management of Severe Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial[NCT02488538] | Phase 3 | 300 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Acoustic startle response (ASR) is measured during the follicular and luteal phase of the menstrual cycle in controls and those with PMDD. Magnitude of ASR is measured using the eyeblink reflex, by recording activity from the orbicularis oculi muscle. Recording is performed via two surface disk electrodes (Ag-AgCl) applied underneath the left eye; one in line with the pupil and one 1-2 cm lateral to the first one. For the primary outcome of baseline ASR magnitude over the menstrual cycle, peak amplitude of the blink reflex was determined in the 20-120-ms time frame following stimulus onset relative to baseline (baseline is the average baseline electromyography (EMG) level for the 50 ms immediately preceding auditory stimulus onset). ASR is measured in microvolts, and raw ASR results are standardized to t-scores. Higher ASR t-score indicates greater contraction of the the orbicularis oculi muscle. A t-score of 50 indicates the population mean with a standard deviation of 10. (NCT02777372)
Timeframe: Month 1 (Follicular), Month 2 (Luteal)
Intervention | t score (Mean) | |
---|---|---|
Month 1 (Follicular) | Month 2 (Luteal) | |
Control | 54.2 | 56.4 |
Sertraline | 53.7 | 53.3 |
This outcome examines the impact of luteal phase treatment with a selective serotonin reuptake inhibitor (SSRI) (PMDD group only) on acoustic startle response (ASR). ASR is measured using the eyeblink reflex, measured by recording activity from the orbicularis oculi muscle. Recording is performed via two surface disk electrodes (Ag-AgCl) applied underneath the left eye; one in line with the pupil and one 1-2 cm lateral to the first one. Peak amplitude of the blink reflex is determined in the 20-120-ms time frame following stimulus onset. PMDD participants complete test day 3 (Luteal Month 3) while on sertraline and their ASR magnitude will be compared to their previous luteal test day (Luteal Month 2). ASR is measured in microvolts, and raw ASR results are standardized to t-scores. Higher ASR t-score indicates greater contraction of the the orbicularis oculi muscle. A t-score of 50 indicates the population mean with a standard deviation of 10. (NCT02777372)
Timeframe: Month 2 (Luteal), Month 3 (Luteal)
Intervention | t score (Mean) | |
---|---|---|
Month 2 (Luteal) | Month 3 (Luteal) | |
Control | 56.4 | 51.8 |
Sertraline | 53.3 | 52.2 |
Blood samples were collected to measure serum interleukin-6 (IL-6). IL-6 levels were compared in the follicular and luteal phases, between Control and PMDD groups. Levels are measured in picogram/milliliter (pg/mL). (NCT02777372)
Timeframe: Month 1 (Follicular ), Month 2 (Luteal )
Intervention | picogram/milliliter (pg/mL) (Mean) | |
---|---|---|
Month 1 (Follicular) | Month 2 (Luteal) | |
Control | 0.4 | .59 |
Sertraline | .34 | .4 |
Blood samples were collected to measure serum TNF-alpha levels in the Follicular and Luteal 1 phases. Levels are measured in picogram/milliliter (pg/mL). (NCT02777372)
Timeframe: Month 1 (Follicular ), Month 2 (Luteal )
Intervention | pg/mL (Mean) | |
---|---|---|
Month 1 (Follicular ) | Month 2 (Luteal ) | |
Control | 1.27 | 1.27 |
Sertraline | 1.63 | 1.54 |
"This study was conducted at Yale University almost two decades ago. Our group at the University of Pennsylvania only has very basic information about this study. This includes the number of participants, which was 18, and the fact that no adverse events occurred. Staff members at the University of Pennsylvania do not have access to any additional study data. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania and we are unable to contact for additional information.~We only know that 18 participants completed, but as far as we know data was never analyzed for these 18 participants." (NCT00626340)
Timeframe: Healthy controls will undergo scans pre and post 3 weeks of estrogen treatment. Women with depression will undergo scans pre and post 6 weeks of treatment with estrogen alone, estrogen and fluoxetine, or fluoxetine alone
Intervention | () |
---|---|
All Participants | 0 |
6 reviews available for gamma-aminobutyric acid and Premenstrual Tension
Article | Year |
---|---|
Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA.
Topics: Biology; Female; gamma-Aminobutyric Acid; Humans; Menstrual Cycle; Premenstrual Dysphoric Disorder; | 2023 |
GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder.
Topics: Female; GABA Modulators; gamma-Aminobutyric Acid; Humans; Luteal Phase; Menstrual Cycle; Pregnanolon | 2023 |
Premenstrual Dysphoric Disorder: Epidemiology and Treatment.
Topics: Diagnosis, Differential; Diagnostic and Statistical Manual of Mental Disorders; Disease Management; | 2015 |
A biopsychosocial approach to premenstrual dysphoric disorder.
Topics: Adult; Child; Child Abuse, Sexual; Depression; Diagnosis, Differential; Diagnostic and Statistical M | 2003 |
The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women.
Topics: Affect; Depression, Postpartum; Female; gamma-Aminobutyric Acid; Humans; Menstruation; Mental Disord | 2006 |
The association between premenstrual dysphoric disorder and other mood disorders.
Topics: Biomarkers; Comorbidity; Depressive Disorder; Diagnosis, Differential; Endorphins; Family; Female; g | 1997 |
12 other studies available for gamma-aminobutyric acid and Premenstrual Tension
Article | Year |
---|---|
Resident intruder paradigm-induced PMDD rat model of premenstrual irritability: behavioral phenotypes, drug intervention, and biomarkers.
Topics: Animals; Biomarkers; Female; gamma-Aminobutyric Acid; Humans; Phenotype; Premenstrual Dysphoric Diso | 2022 |
Resident intruder paradigm-induced PMDD rat model of premenstrual irritability: behavioral phenotypes, drug intervention, and biomarkers.
Topics: Animals; Biomarkers; Female; gamma-Aminobutyric Acid; Humans; Phenotype; Premenstrual Dysphoric Diso | 2022 |
Resident intruder paradigm-induced PMDD rat model of premenstrual irritability: behavioral phenotypes, drug intervention, and biomarkers.
Topics: Animals; Biomarkers; Female; gamma-Aminobutyric Acid; Humans; Phenotype; Premenstrual Dysphoric Diso | 2022 |
Resident intruder paradigm-induced PMDD rat model of premenstrual irritability: behavioral phenotypes, drug intervention, and biomarkers.
Topics: Animals; Biomarkers; Female; gamma-Aminobutyric Acid; Humans; Phenotype; Premenstrual Dysphoric Diso | 2022 |
The correlation between neurosteroids and neurotransmitters with liver yang rising and liver qi stagnation types of premenstrual syndrome.
Topics: Adult; Dehydroepiandrosterone; Dopamine; Female; gamma-Aminobutyric Acid; Humans; Liver; Medicine, C | 2014 |
Shu‑Yu capsule, a Traditional Chinese Medicine formulation, attenuates premenstrual syndrome depression induced by chronic stress constraint.
Topics: Animals; Body Mass Index; Depression; Drugs, Chinese Herbal; Female; Fluoxetine; gamma-Aminobutyric | 2014 |
Prefrontal GABA concentration changes in women-Influence of menstrual cycle phase, hormonal contraceptive use, and correlation with premenstrual symptoms.
Topics: Contraceptives, Oral, Hormonal; Creatine; Estradiol; Female; Follicle Stimulating Hormone; gamma-Ami | 2015 |
Pregabalin and edema in young women suffering from premenstrual syndrome.
Topics: Adult; Analgesics; Anxiety Disorders; Edema; Female; gamma-Aminobutyric Acid; Humans; Pregabalin; Pr | 2010 |
Easing the burden of premenstrual dysphoric disorder.
Topics: Contraceptives, Oral, Hormonal; Diagnostic and Statistical Manual of Mental Disorders; Diet; Dietary | 2013 |
Hormonally regulated alpha(4)beta(2)delta GABA(A) receptors are a target for alcohol.
Topics: Animals; Chlorides; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Female; gamma | 2002 |
Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study.
Topics: Adult; Cerebral Cortex; Estradiol; Female; Follicular Phase; gamma-Aminobutyric Acid; Humans; Luteal | 2002 |
Hypothalamic, pineal and pituitary factors in the premenstrual syndrome.
Topics: Female; gamma-Aminobutyric Acid; Humans; Premenstrual Syndrome; Serotonin | 1983 |
Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder.
Topics: Adult; Depressive Disorder; Female; Follicular Phase; gamma-Aminobutyric Acid; Humans; Luteal Phase; | 1996 |
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid; | 1998 |
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid; | 1998 |
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid; | 1998 |
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid; | 1998 |
[Premenstrual syndrome].
Topics: Affect; Brain; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Premenstrual Syndr | 2002 |